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ABSTRACT
A pilot study was performed to obtain preliminary data regarding the need for targeted therapy of
bacterial vaginosis (BV) when it accompanies clinically defined cervicitis. Specifically, women
attending a sexually transmitted disease (STD) clinic with clinically defined BV and cervicitis were
treated in the first phase of the study with doxycycline alone. In phase II, the patients received
doxycycline and concomitant intravaginal metronidazole gel. All patients were reexamined 3-4
weeks after therapy. Persistence ofBV occurred in 18/19 (95%) ofwomen in phase I vs. 1/7 (14%) of
women in phase II (P < 0.001). We concluded that, in women with coexistent clinically defined
cervicitis and BV, the treatment of cervicitis does not result in a normalization of the vaginal flora.
(C) 1995 Wiley-Liss, Inc.
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he coexistence of bacterial vaginosis (BV) and
cervicitis is frequently observed by clinicians
and is well documented in the literature.
1-4 As
many as 50% ofthe women attending sexually trans-
mitted disease (STD) clinics with clinically defined
cervicitis have BV.
3 Despite the frequent coexist-
ence of these syndromes, no formal recommenda-
tions for the appropriate clinical management of
patients with BV and cervicitis exist. In practice,
many clinicians treat only the endocervical infections
in such women. To begin to examine the management
ofBV in the setting of cervicitis and to determine the
optimal therapy for patients with both syndromes, we
conducted a pilot study ofwomen with BV and cervi-
citis attending an inner-city STD clinic.
SUBJECTS AND METHODS
Women presenting to the Chicago Department of
Health STD Clinic with a clinical diagnosis of BV
and concomitant cervicitis who were seen by the 2
study clinicians were eligible for the study. The
study was approved by the Internal Review Board
of the Chicago Department of Health and an in-
formed consent was obtained from each participant.
A patient was enrolled based on the investigator’s
assessment of her probable compliance and willing-
ness to return for a follow-up visit. A patient was
excluded if she had evidence of fungal or trich-
omonal vaginitis or if she was pregnant. The pa-
tients were examined according to a standardized
clinical protocol. A speculum examination was per-
formed, and the presence and amount of vaginal
discharge were noted. Secretions in the vaginal vault
were collected with a cotton-tipped swab. The pH
of the secretions was determined using pH indica-
tor strips (EM Science, Gibbstown, NJ). The vag-
inal fluid, diluted in saline, was examined micro-
scopically and the presence of pseudohyphae,
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trichomonads, or clue cells was noted. A whiff test
was performed using 10% KOH, and a vaginal
smear was air-dried for later microscopic evalua-
tion. The ectocervix was cleaned with large cotton
swabs and the endocervix examined for signs of
inflammation. An endocervical swab was obtained
for Gram’s stain and culture of Neisseria gonor-
rhoeae, which was processed using standard labora-
tory methods, s A second endocervical swab was
collected for chlamydia testing (EIA or DNA
probe). A bimanual examination was performed.
The clinical diagnosis of BV was based on Am-
sel’s criteria and required the presence of 3 of the
following findings: homogenous vaginal discharge,
pH >4.5, positive whiff test, and clue cells.
6 Cervi-
citis was defined as a clinical observation of a yellow
endocervical discharge. The presence of endocervical
bleeding and increased numbers of endocervical neu-
trophils (>30 per oil immersion field within the en-
docervical mucus) was also recorded. 1,7,8
Vaginal Gram’s stains for the diagnosis of BV
were interpreted in a blinded fashion using the scor-
ing system ofNugent et al.
9 The quantitation of poly-
morphonuclear leukocytes on the endocervical smears
was performed as described by Brunham et al.
7
The study was divided into 2 phases. During the
first phase, the patients were treated for cervicitis
with doxycycline, 100 mg p.o.b.i.d, for 7 days, or
doxycycline plus cefixime, 400 mg p.o. dose,
depending on the results ofthe endocervical Gram’s
stain. No treatment for BV was provided at the initial
visit. The patients were asked to refrain from unpro-
tected sexual intercourse and to return for a second
visit in 3-4 weeks. At visit 2, the patients were reex-
amined, and repeat vaginal wet preparations and
smears and endocervical smears were obtained. The
patients were questioned about interim sexual prac-
tices, symptoms, and douching. If BV was still
present, the patients were treated at that time with oral
metronidazole, 500 mg p.o.b.i.d, for 7 days.
1
Phase II was conducted in the same manner
except that the patients received treatment at visit
for their endocervical infections and for BV. To
avoid multiple oral antibiotics, we prescribed topi-
cal metronidazole gel (one applicator intravaginally
b.i.d, for 5 days).
RESULTS
Thirty-one patients were enrolled in this pilot study.
Between November 1992 and September 1993, 23
TABLE I. Comparison of evaluable patients in phase
land II at enrollment
Phase Phase II P
(N 19) (N 7) value
Mean age (years) 26.7 30.0 NS
Race (African American) 19/19 (100%) 7/7 (100%) NS
Symptoms at visit
Vaginal discharge 15/19 (79%) 5/7 (71%) NS
Odor 6/19 (32%) 4/7 (57%) NS
Gonorrhea or chlamydia 2/19 (10%)b’c 0/7 (0%) NS
at visit
NS not significant.
bChlamydia test results unavailable for 2 patients.
CGonorrhea test results unavailable for patient.
women were enrolled for phase I. Nineteen (83%)
of these patients returned for visit 2. Eight patients
were enrolled in phase II between September 1993
and April 1994. One patient failed to return for
visit 2. There were no significant differences in the
study groups in age, race, symptomatology, or iso-
lation rates of N. gonorrhoeae or Chlamydia tra-
chomatis (Table 1).
At the follow-up visit, only one patient treated
for cervicitis admitted to noncompliance with the
doxycycline regimen. She had taken the medication
for 5 of the 7 days. Four of 19 (21%) women in
phase I and 1/7 (14%) women in phase II admitted
to unprotected intercourse during the study period.
At the time of their return visits, 18/19 (95%)
patients in phase I had persistent BV based on the
clinical criteria
5 compared with only 1/7 (14%)
metronidazole-treated patients (P < 0.001) (Table
2). For phase I, vaginal Gram’s stains were avail-
able for 12 patients and all stains confirmed the
clinical diagnosis ofBV. No Gram’s stain specimen
was available to confirm the absence of BV in the
single patient without clinical findings (this patient
admitted to douching 2 days prior to her return
visit). For phase II, vaginal Gram’s stains were
available to confirm the clinical findings for all
patients. Although a persistence of clinical cervici-
tis was noted in 9/19 (47%) women in phase I vs.
only 1/7 (14%) women in phase II, this difference
was not statistically significant. The vaginal dis-
charge symptoms resolved in 9/15 (60%) of phase I
participants vs. 4/5 (80%) in phase II. A resolution
of vaginal odor was noted by 3/6 (50%) in phase I
vs. 4/4 (100%) in phase II. Neither finding was
statistically significant.
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TABLE 2. Comparison of study populations
at visit 2
Phase Phase II P value
Symptoms
Resolution of vaginal 9/15 (60%) 4/5 (80%) NS
discharge
Resolution of odor 3/6 (50%) 4/4 (100%) NS
Signs
Persistence of cervicitis 9/19 (47%) I/7 (14%) NS
Presence of BV 18/19 (95%) I/7 (14%) <0.001
aNS not significant.
DISCUSSION
BV is characterized by a dramatic shift in vaginal
microbial ecology. The normal lactobacilli-predom-
inant flora is replaced by increased concentrations
ofanaerobic and facultative anaerobic flora.
12 How-
ever, the pathogenesis, including whether the dis-
appearance of the lactobacilli is a primary cause or a
result, is unknown.
13,14 The syndrome ofBV most
commonly occurs among sexually active women
and frequently coexists with other STDs.
1-4 Up to
50% of women attending STD clinics with mu-
copurulent cervicitis also have BV.
3 In fact, the
frequent coexistence of cervicitis and BV has led
some investigators to question whether local factors
associated with cervical inflammation may predis-
pose to alterations in the vaginal flora.’ls
At a practical level, the most appropriate treat-
ment of women with both syndromes is an impor-
tant consideration. Despite the fact that the success-
ful treatment ofBV requires an antimicrobial agent
with excellent activity against anaerobes, many prac-
titioners feel that the treatment of cervicitis alone
may result in a resolution ofBV in this setting. Also
of concern is that the potential gastrointestinal side
effects associated with doxycycline and metronida-
zole might lead to poor patient compliance. The
current availability of efficacious topical prepara-
11,16 tions for treating BV obviates that concern,
although their added expense is a factor to be con-
sidered.
Our data suggest that treatment specific for both
BV and cervicitis is necessary in order to promptly
reestablish the normal vaginal ecology. Although
the number of patients studied in this pilot study
was small, the prospective nature ofthe study, com-
bined with the strikingly different results between
the 2 treatment groups, makes the results worthy of
comment and suggests the need for further investi-
gation. Further studies should include a larger
number of patients from various health-care set-
tings in a randomized, placebo-controlled study
design.
Only 7% of the patients in our study had N.
gonorrhoeae or C. trachomatis isolated as a cause of
their cervicitis. Chlamydia testing was likely ham-
pered by our lack of access to more sensitive diag-
nostic techniques such as cell culture or polymerase
chain reaction (PCR); however, just like its male
counterpart, nongonococcal urethritis, no pathogen
is isolated from the majority of women with mu-
copurulent cervicitis.
17 Nonetheless, in a high-risk
setting such as an STD clinic, the treatment of
women with clinical signs of cervicitis is war-
ranted.
17 Future studies with a larger study popu-
lation should allow for meaningful analyses of sub-
sets of patients with various etiologies of cervicitis.
Of interest is that 86% of the women who were
treated simultaneously with doxycycline and met-
ronidazole had clinical resolution of their cervicitis
at visit 2 compared with 53% of women who did
not receive metronidazole at visit 1. Although not
statistically significant, this finding raises the ques-
tion of a possible role for anaerobes in the etiology
of cervical inflammation.
In summary, we have shown that the simulta-
neous treatment of BV and cervicitis is effective in
eradicating BV in women who present with both
syndromes. The failure to specifically treat BY re-
suited in the persistence of abnormal vaginal flora.
As more information becomes available on the po-
tential complications of BV and the protective role
of vaginal lactobacilli against vaginal and cervical
infections, the prompt resolution of BV may as-
sume even greater importance.
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